A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 …
KR Chapman, KM Beeh, J Beier, ED Bateman… - BMC pulmonary …, 2014 - Springer
Background Two once-daily long-acting muscarinic antagonists (LAMAs) are currently
available for the treatment of chronic obstructive pulmonary disease (COPD)–tiotropium and …
available for the treatment of chronic obstructive pulmonary disease (COPD)–tiotropium and …
Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies
A D'Urzo, E Kerwin, T Overend… - … medical research and …, 2014 - Taylor & Francis
Background: Glycopyrronium is a once daily (od) long-acting muscarinic antagonist that is
approved for maintenance treatment of COPD. This post-hoc pooled analysis of two phase III …
approved for maintenance treatment of COPD. This post-hoc pooled analysis of two phase III …
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
R Buhl, D Banerji - International journal of chronic obstructive …, 2012 - Taylor & Francis
Bronchodilators are central in the symptomatic management of chronic obstructive
pulmonary disease (COPD). Long-acting muscarinic antagonists (LAMAs) and long-acting …
pulmonary disease (COPD). Long-acting muscarinic antagonists (LAMAs) and long-acting …
Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data
AD D'Urzo, EM Kerwin, KR Chapman… - … Journal of Chronic …, 2015 - Taylor & Francis
Background Chronic use of inhaled anticholinergics by patients with chronic obstructive
pulmonary disease (COPD) has raised long-term safety concerns, particularly …
pulmonary disease (COPD) has raised long-term safety concerns, particularly …
Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and …
Background Morning symptoms associated with COPD have a negative impact on patients'
quality of life. Long-acting bronchodilators with rapid onset may relieve patients' symptoms …
quality of life. Long-acting bronchodilators with rapid onset may relieve patients' symptoms …
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN …
PA Frith, PJ Thompson, R Ratnavadivel, CL Chang… - Thorax, 2015 - thorax.bmj.com
Background The optimal use of various therapeutic combinations for moderate/severe
chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial compared the …
chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial compared the …
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
E Kerwin, J Hébert, N Gallagher… - European …, 2012 - Eur Respiratory Soc
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist
(LAMA) in development for chronic obstructive pulmonary disease (COPD). The …
(LAMA) in development for chronic obstructive pulmonary disease (COPD). The …
Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study
C Wang, T Sun, Y Huang, M Humphries… - … journal of chronic …, 2015 - Taylor & Francis
Background Glycopyrronium is a once-daily (od) long-acting muscarinic antagonist for the
maintenance treatment of chronic obstructive pulmonary disease (COPD). The GLOW7 …
maintenance treatment of chronic obstructive pulmonary disease (COPD). The GLOW7 …
Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis
AS Ismaila, EL Huisman, YS Punekar… - International journal of …, 2015 - Taylor & Francis
Background Randomized, controlled trials comparing long-acting muscarinic antagonist
(LAMA) efficacy in COPD are limited. This network meta-analysis (NMA) assessed the …
(LAMA) efficacy in COPD are limited. This network meta-analysis (NMA) assessed the …
A novel model-based approach for dose determination of glycopyrronium bromide in COPD
H Arievich, T Overend, D Renard, M Gibbs… - BMC Pulmonary …, 2012 - Springer
Background Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic
antagonist in development for treatment of COPD. This study compared the efficacy and …
antagonist in development for treatment of COPD. This study compared the efficacy and …
相关搜索
- efficacy and safety patients with copd
- muscarinic antagonist patients with copd
- efficacy and safety muscarinic antagonist
- muscarinic antagonist blinded evaluation
- blinded evaluation patients with copd
- efficacy and safety blinded evaluation
- inhaled glycopyrronium patients with copd
- placebo and tiotropium patients with copd
- muscarinic antagonist glycopyrronium bromide
- health status patients with copd
- muscarinic antagonist clinical benefit
- bronchodilator action copd patients
- pulmonary function copd patients
- salmeterol fluticasone patients with copd
- comprehensive analysis patients with copd
- efficacy and safety tiotropium in patients